| Date Filed | Type | Description |
| 08/16/2023 |
4
| Silver Ronald (Principal Accounting Officer) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Sold 1,976 shares
@ $10.04, valued at
$19.8k
|
|
| 08/16/2023 |
4
| John Minardo (Chief Legal Officer) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Sold 7,045 shares
@ $10.04, valued at
$70.7k
|
|
| 08/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/07/2023 |
SC 13D
| IRONWOOD PHARMACEUTICALS INC reports a 97.6% stake in VectivBio Holding AG |
| 07/05/2023 |
SC 13G/A
| WESTFIELD CAPITAL MANAGEMENT CO LP reports a 0% stake in Ironwood Pharmaceuticals, Inc. |
| 06/30/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-B...|
Docs:
|
"Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares BOSTON and BASEL, Switzerland – June 29, 2023 – Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, and VectivBio Holding AG , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio for $17.00 per share in cash . The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments to tender 2,007,310 additional Shares under the guaran..." |
|
| 06/29/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/16/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
4
| MCCOURT Thomas A (CEO) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Sold 26,632 shares
@ $10.7, valued at
$285k
|
|
| 05/31/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 05/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/24/2023 |
4
| Shetzline Michael (CMO,SVP,Head-Res&Drug) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Sold 10,324 shares
@ $10.12, valued at
$104.5k
|
|
| 05/24/2023 |
4
| Davis Andrew (SVP, Chief Business Officer) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Sold 6,305 shares
@ $10.12, valued at
$63.8k
|
|
| 05/24/2023 |
4
| MCCOURT Thomas A (CEO) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Sold 36,000 shares
@ $10.12, valued at
$364.3k
|
|
| 05/23/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in Ironwood Pharamaceuticals, Inc. |
| 05/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Moukheibir Catherine (Director) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Granted 1,677 shares
@ $0 |
|
| 03/17/2023 |
4
| DENNER ALEXANDER J (10% Owner) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Granted 1,438 shares
@ $0 |
|
| 03/10/2023 |
4
| Silver Ronald (Principal Accounting Officer) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Granted 35,620 shares
@ $0 |
|
| 03/10/2023 |
4
| Shetzline Michael (CMO,SVP,Head-Res&Drug) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC|
Txns:
| Granted 69,869 shares
@ $0
Granted 34,935 options to buy
@ $0 |
|
|